Title

Biomarkers in systemic sclerosis.

Authors

Susan V. Castro, Thomas Jefferson UniversityFollow
Sergio A. Jimenez, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

2-1-2010

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Biomarkers in Medicine Volume 4, Issue 1, February 2010, Pages 133-147. The published version is available at DOI: 10.2217/bmm.09.79. Copyright © Future Medicine Ltd

Abstract

Systemic sclerosis is an autoimmune inflammatory disorder of unknown etiologycharacterized b y pronounced fibroproliferative alterations in the microvasculature, and frequent cellular and humoral immunity abnormalities, culminating in a severe and often progressive fibrotic process. Numerous biomarkers reflecting the three main pathogenetic mechanisms in systemic sclerosis have been described; however, aside from several disease-specific autoantibodies, other biomarkers have not been thoroughly validated and require further study. Thus, there is an unmet need for validated biomarkers for diagnosis, disease classification, and evaluation of organ involvement and therapeutic response in systemic sclerosis.

Recommended Citation

Castro, Susan V. and Jimenez, Sergio A., "Biomarkers in systemic sclerosis." (2010). Scleroderma Center Faculty Papers. Paper 4.
https://jdc.jefferson.edu/sclerodermafp/4

PubMed ID

20387310